HORIZON-HLTH-2024-DISEASE-08-20: Biomarcadores y sistemas de liberación para desarrollo de vacunas de células T virales
Referencia : RDRFR20240126017
Caduca : 2024-04-05 00:00:00
The project aims to develop vaccines that activate T cell for viral diseases. Together the partners will develop a new generation of dengue vaccine which target development of dengue specific T cell response. In parallel, the project will design and test immunogenicity of T cell epitopes of other flaviviruses including Zika virus, West-Nile virus. The French research institute is currently looking for a SME with expertise in biomarkers and vaccine delivery systems.
The French research institute is dedicated to the study of biology, micro-organisms, diseases and vaccines. It has been at the forefront of the fight against infectious diseases since its creation in the 19th century. The project has 2 specific aims: 1. Develop surrogate markers for immune-protection against dengue and other flavivirus diseases– Zika, West-Nile, etc. 2. Study vaccine deliver systems which activate T cells Aim 1 - The project will study immunological profiles (dengue specific -CD4, CD8, memory T cell, memory B cell, antibody profiles) of a cohort consist of dengue infected individuals and flaviviruses seronegative individuals living in dengue endemic regions. The objective will be to follow them for all fever episodes during the next 3 years and identified virology confirmed dengue cases. It will correlate immunological profiles with protection against dengue disease and hospitalized/severe dengue. It aims at identify surrogate markers for protection against dengue disease and develop an assay which is sensitive, robust and easy to use for “beyond phase 1” vaccine trial. Aim 2 – Together the partners will study vaccine delivery systems which activate T cells. They will use murine and non-human private to study immunogenicity of the vaccine delivery systems using our dengue T cell epitopes. The project will compare immunological profiles after vaccination compare with natural dengue infection and current tetravalent live attenuated dengue vaccine. The best candidate vaccine will be tested using dengue disease mouse model. To well-answer the HORIZON-HLTH-2024-DISEASE-08-20 call, the French institute is looking for a SME with expertise in biomarkers and vaccine delivery systems, mainly: - developing assay to quantify viral specific T cell response - providing vaccine delivery system which activate T cell response, which could be encapsulated mRNA, viral vector, adjuvants, etc. Advantages and innovation The advantages of viral T cell vaccine are: 1. Avoiding and minimizing side effect induced by antibodies such as antibody dependent enhancement (ADE) which is an important factor for development of severe dengue. 2. Well-balanced immuno-protection against all 4 dengue serotypes because of the conserved regions of the T cell epitopes. 3. Long-lived immunity from T follicular helper cells. 4. Possibility to add T cell epitopes of other viruses in one component. Technical Specification or Expertise Sought 1. T cell assay development 2. Vaccine delivery system which activate T cells which could be encapsulated mRNA, viral vector, adjuvants, etc. Framework program Access to finance Call title and identifier HORIZON-HLTH-2024-DISEASE-08-20 Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential Submission and evaluation scheme Single-stage submission scheme Anticipated project budget 7 to 8 million Coordinator required No Deadline for EoI 05/04/2024 Deadline of the call 11/04/2024 Project duration in weeks 260 Web link to the call https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-08-20 Project title and acronym Viral T cell vaccine
Si estás interesado en recibir más información ponte en contacto con nosotros aquí
En esta página se encuentra una selección de oportunidades de colaboración tecnológica que se han extraído de la base de datos global de la Enterprise Europe Network que puede consultar en la web del consorcio EEN-GalacteaPlus , del cual FICYT es entidad coordinadora. También se incluye una selección de brokerage events y misiones, así como las convocatorias de programas europeos que se consideran más importantes para las empresas del Principado de Asturias.